NextPlat (NASDAQ:NXPL) Releases Quarterly Earnings Results

NextPlat (NASDAQ:NXPL) released its earnings results on Thursday. The company reported ($0.42) earnings per share (EPS) for the quarter, Zacks reports. NextPlat had a negative return on equity of 53.22% and a negative net margin of 21.56%.

Here are the key takeaways from NextPlat’s conference call:

• NextPlat said its turnaround is largely complete, with Q1 showing record-level gross margins, lower operating expenses, and a clear path to improving profitability in the second half of 2026.
• The healthcare segment posted a major improvement, with gross margin rising to 39% from about 20% a year ago and the segment generating positive operating income for the quarter.
• The company secured five new 340B pharmacy service agreements in the quarter, a record, and expects those customers to begin contributing to revenue in the third quarter after onboarding.
• Management highlighted new growth initiatives, including a nationwide fulfillment partnership and a planned e-commerce healthcare site that will sell prescription drugs, GLP-1 products, and OTC items, expected to launch before the end of Q2.
• Quarterly revenue declined year over year to about $10 million, though the company said the mix is shifting toward higher-margin contract and fulfillment revenue, while e-commerce remained steady at about $3.2 million.

NextPlat Trading Down 2.3%

NXPL stock traded down $0.15 during midday trading on Thursday, reaching $6.26. 16,641 shares of the company’s stock traded hands, compared to its average volume of 12,016. The company has a market capitalization of $16.96 million, a P/E ratio of -1.42 and a beta of 1.91. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.65 and a quick ratio of 2.27. NextPlat has a fifty-two week low of $3.38 and a fifty-two week high of $11.10. The business has a 50-day moving average price of $5.42 and a two-hundred day moving average price of $6.07.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NextPlat stock. Citadel Advisors LLC purchased a new stake in shares of NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.19% of NextPlat as of its most recent SEC filing. 1.30% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.